Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Summary

The purpose of this phase I/II trial is to evaluate the safety and efficacy of anti-KRAS G12D mTCR cells among HLA-A 1101 positive pancreatic cancer patients. HLA and biomarker testing to determine if patient is eligible will be done during screening for the trial; however, prior reports are encouraged.

General Information

NCT#: NCT03745326
Study ID: 190017
Trial Phase: Phase I/II

Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Cyclophosphamide, Aldesleukin, Fludarabine, anti-KRAS G12D mTCR cells

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search